TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 26.09 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $20.869 million which missed the analyst consensus estimate of $21.047 million by 0.85 percent. This is a 18.24 percent increase over sales of $17.649 million the same period last year.